Guardian Pharmacy Services (NYSE:GRDN) Stock Rating Upgraded by Wall Street Zen

Key Points

• Wall Street Zen upgraded Guardian Pharmacy Services from “hold” to “buy,” while analysts overall maintain a “Moderate Buy” consensus with a $43.83 average price target.
• Guardian reported quarterly EPS of $0.29, beating estimates of $0.26, and revenue of $351.77 million versus the $340.45 million consensus estimate.
• GRDN shares were reported up 9.8%, opening at $43.35, near their 12-month high of $47.02; several institutional investors have also recently initiated or increased positions.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday.

Other equities research analysts have also issued reports about the stock. Oppenheimer boosted their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an "outperform" rating in a report on Friday. Zacks Research downgraded shares of Guardian Pharmacy Services from a "strong-buy" rating to a "hold" rating in a research note on Monday, May 11th. Weiss Ratings upgraded shares of Guardian Pharmacy Services from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday. Truist Financial lifted their price target on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a "buy" rating in a report on Wednesday, June 17th. Finally, Bank of America boosted their price objective on shares of Guardian Pharmacy Services from $42.00 to $47.00 and gave the stock a "buy" rating in a research note on Wednesday, June 17th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $43.83.

Guardian Pharmacy Services Trading Up 9.8%

Shares of GRDN stock opened at $43.35 on Friday. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of 42.09, a PEG ratio of 2.87 and a beta of 0.10. The business's 50-day moving average price is $40.93 and its 200-day moving average price is $37.09. Guardian Pharmacy Services has a 12 month low of $19.30 and a 12 month high of $47.02.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.03. The company had revenue of $351.77 million during the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a return on equity of 31.45% and a net margin of 4.50%. On average, sell-side analysts predict that Guardian Pharmacy Services will post 1.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Guardian Pharmacy Services

A number of hedge funds have recently added to or reduced their stakes in the business. First Trust Advisors LP acquired a new stake in Guardian Pharmacy Services in the 1st quarter valued at $3,528,000. SG Americas Securities LLC increased its stake in Guardian Pharmacy Services by 274.9% during the 4th quarter. SG Americas Securities LLC now owns 19,017 shares of the company's stock valued at $572,000 after purchasing an additional 13,945 shares in the last quarter. TimesSquare Capital Management LLC raised its holdings in Guardian Pharmacy Services by 21.9% during the fourth quarter. TimesSquare Capital Management LLC now owns 1,048,136 shares of the company's stock worth $31,538,000 after buying an additional 187,963 shares during the last quarter. Jennison Associates LLC acquired a new position in Guardian Pharmacy Services during the fourth quarter worth $3,489,000. Finally, Globeflex Capital L P bought a new position in shares of Guardian Pharmacy Services in the fourth quarter valued at $1,335,000.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source